Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 5, 2013, Pages 1159-1171

  Wu, Hao ^a   Huang, Min ^a   Lu, Mingjie ^a   Zhu, Wei ^a   Shu, Yongqian ^a   Cao, Peng ^b   Liu, Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

Drug resistant; Gastric cancer; MAPT; Methylation; miR 34c 5p; Paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATE; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 34C 5P; PACLITAXEL; TAU PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING SITE; BISULFITE SEQUENCING; CANCER CELL; CANCER RESISTANCE; CANCER TISSUE; CELL ASSAY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC PROCEDURES; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MALE; MICRORNAS; MIDDLE AGED; PACLITAXEL; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TAU PROTEINS;

EID: 84877926074     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2108-y     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA et al (2010) NCCN gastric cancer panel. Gastric cancer. J Natl Compr Canc Netw 8:378-409
3. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M et al (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3210-3216
4. Takeyoshi I, Makita F, Tanahashi Y, Iwazaki S, Ogawa T et al (2011) A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer. Anticancer Res 31:287-291
5. Ludwig AH, Kupryjañczyk J (2006) Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin Cancer Res 12:6204
6. Gao J, Lu M, Yu JW, Li YY, Shen L (2011) Thymidine phosphorylase/β- tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11:177
7. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1-19
8. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L (2005) Microtubule-associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4:1149-1152
9. Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ et al (2009) The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci 66:504-515
10. Ouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320
11. Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B et al (2011) The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 68:553-557
12. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141-1154
13. Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M et al (2006) Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 94:1894-1897
14. Zheng T, Wang J, Chen X, Liu L (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126:2-10
15. Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46:298-311
16. Ma J, Dong C, Ji C (2010) MicroRNA and drug resistance. Cancer Gene Ther 17:523-531
17. Lee Rosalind C, Feinbaum Rhonda L, Ambros Victor (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854
18. Sarkar Fazlul H, Li Yiwei, Wang Zhiwei, Kong Dejuan et al (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13:57-66
19. Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A et al (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30:4386-4398
20. Brabletz T (2012) MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle 11:215-216
21. Cannell IG, Bushell M (2010) Regulation of Myc by miR-34c: a mechanism to prevent genomic instability? Cell Cycle 9:2726-2730
22. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA et al (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127:2768-2776
23. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G et al (2012) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 27. doi: 10.1038/onc.2012.51
24. Kurbacher CM, Cree IA (2005) Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med 110:101-120
25. Benes V, Castoldi M (2010) Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50:244-249
26. Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical aspects of microRNA target prediction. Curr Mol Med 11:93-109
27. Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R (2010) Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 30:3557-3564
28. Sharma N, Ramachandran S, Bowers M, Yegappan M, Brown R et al (2000) Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. Cancer Chemother Pharmacol 46:329-337
29. Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H (2010) The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 12:R43
30. Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167-7172
31. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320
32. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X, Liu Z (2012) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene doi: 10.1038/onc.2012.432
33. He C, Xiong J, Xu X, Lu W, Liu L (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388:35-40
34. Agirre X, Martínez-Climent JA, Odero MD, Prósper F (2012) Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 26:395-403
35. Hata A, Davis BN (2011) Regulation of pri-miRNA processing through Smads. Adv Exp Med Biol 700:15-27
36. Kim NH, Kim HS, Kim NG, Lee I, Choi HS (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 4:ra71
37. Wong MY, Yu Y, Walsh WR, Yang JL (2011) microRNA-34 family and treatment of cancers with mutant or wild-type p53. Int J Oncol 38:1189-1195
38. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T et al (2011) Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17:4965-4974